UFE causes significant volume reduction of myomas and clinical improvement. MRI can reveal remaining vascularization in myomas despite angiographically complete embolization of uterine arteries.
<p><strong>Objective. </strong>Lysozyme is a natural antimicrobial and immunomodulatory enzyme, which is produced as a host response to infectious agents. The objective of this study was to compare the efficacy and safety of lysozyme-based versus benzydamine and chlorhexidinebased oral spray in patients with an acute tonsillopharyngitis associated with a common cold.</p><p><strong>Patients and Methods. </strong>A prospective twoarm pilot study (lysozyme/cetylpyridinium/lidocaine spray versus: benzydamine spray—arm 1; chlorhexidine/lidocaine spray—arm 2) was conducted in the primary health care unit. Efficacy was evaluated by the patient’s self-assessment of pain, difficulty in swallowing and the throat swelling, by using the visual analog scale (VAS) at baseline and three follow-up visits. Safety was evaluated by the assessment of the frequency and severity of adverse effects.</p><p><strong>Results. </strong>Lysozyme-based spray reduced pain faster than benzydamine-based spray and slower than chlorhexidine-based spray. Lysozyme-based and chlorhexidinebased sprays similarly reduced difficulty in swallowing, but were faster than benzydamine-based spray. Similar effects on the reduction of throat swelling were seen in all treated groups. All tested products showed proper safety and were well tolerated, with no serious adverse events reported.</p><p><strong>Conclusions. </strong>The lysozyme-based oral spray was shown to be effective and safe in the reduction of pain, difficulty in swallowing and throat swelling in patients with acute tonsillopharyngitis associated with a common cold. Lysozyme-based oral spray (containing natural compound with advantages of influencing immune system and preventing recurrences) had similar activity to benzydamine and chlorhexidine-based oral antiseptic sprays.</p>
Uvod. Hronični rinosinuzitis sa nosnosinusnom polipozom je hronični upalniproces sluznice nosnih i paranazalnih sinusa koji se klinički manifestujepojavom polipoznih masa u nosnoj šupljini. Prisustvo polipa u nosnimi paranazalnim šupljinama izaziva karakteristične simptome koji utiču nakvalitet života pacijenta. U ovoj studiji je ispitana povezanost između endoskopskog,mikrobiološkog, radiološkog nalaza i težine simptoma pacijenatasa hroničnim rinosinuzitisom i nosnosinusnom polipozom.Metode. Istraživanjem je obuhvaćeno 45 pacijenata sa hroničnim rinosinuzitisomi nosnosinusnom polipozom, kod kojih je indikovano operativnoliječenje nakon neuspjeha konzervativne terapije i 25 ispitanika kontrolnegrupe. Intenzitet simptoma kod ispitanika je procjenjivan na osnovu vizuelneanalogne skale. Svim bolesnicima je urađeno bakteriološko ispitivanjesekreta srednjeg nosnog hodnika. Klinička i radiološka procjena težineoboljenja je vršena na osnovu endoskopskog i skora kompjuterizovanetomografije (CT).Rezultati. Utvrdili smo značajnu statističku razliku u težini simptoma izmeđueksperimetalne i kontrolnu grupe. Endoskopski skor je statistički značajnokorelirao sa težinom simptoma (r = 0,315; p = 0,035), CT-skorom (r = 0,720;p < 0,001) i prisustvom astme (r = 0,335; p = 0,025)). CT skor je statističkiznačajno korelirao sa prisustvom astme (r = 0,419; p = 0,004). Binarnom logističkomregresijom smo utvrdili statistički značajnu povezanost izmeđuendoskopskog skora i težine simptoma (OR = 1,513; p = 0,044).Zaključak. U odnosu na objektivne kliničke parametre, težina simptomakod pacijenata sa nosnosinusnom polipozom statistički značajno korelirasa endoskopskim skorom.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.